Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population. (PubMed, Expert Rev Vaccines) - "Scenario analyses showed that PCV20 remained dominant under a 2 + 1 dosing schedule. Vaccination with PCV20, whether in a 2 + 1 or a 3 + 1 schedule, was estimated to be a dominant vaccination strategy over PCV15 or PCV13 for the prevention of pneumococcal disease in Greek infants, as expansion of serotype coverage prevents additional morbidity and costs."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

VIVID: Vaccine Immunity and Inflammation in the Aging Person Living With HIV (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Hennepin Healthcare Research Institute | Trial completion date: Dec 2030 ➔ Jun 2029 | Trial primary completion date: Dec 2029 ➔ Sep 2028

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years in Singapore. (PubMed, Value Health Reg Issues) - "Cost-effectiveness analysis suggests use of PCV20-in lieu of current Singapore Ministry of Health recommendations for adult pneumococcal vaccination-would represent a cost-effective use of scarce healthcare resources."

HEOR • Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

0100 - INDUSTRY SYMPOSIUM 04 (NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT): From Data to Vaccination: Understanding the Science and Need for PCV20 (ESPID 2025) - "A panel of leading experts will examine the evolving epidemiology of pediatric pneumococcal disease, the critical need for broader serotype coverage, and the anticipated impact of next-generation pneumococcal conjugate vaccines (PCVs). With a particular focus on PCV20, discussions will highlight the pressing need for its timely implementation in national immunization programs to address gaps in protection and prevent unnecessary disease burden."

CME • Infectious Disease • Pneumococcal Infections

Advancing Health Economics: Incorporating AMR Impact Into Pneumococcal Vaccine Assessment (ISPOR 2025) - "This pragmatic modelling approach effectively demonstrates the significant potential of PCV infant immunization in reducing antibiotic prescriptions and resistance. Additionally, the framework has identified key data gaps necessary for improving future modelling efforts. These findings advocate for the inclusion of AMR into cost-effectiveness models and to incorporate AMR impact into the health technology assessment and appraisals of vaccines."

HEOR • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

Meta-analysis of Economic Evaluations of Higher-Valent Pneumococcal Conjugate Vaccines For Seniors in High-Income Countries (ISPOR 2025) - "This study suggests that higher-valent PCVs are generally cost-effective for the senior population in high-income countries, including PCV20 relative to PCV15. These findings can provide valuable insights for vaccination policy decisions in regions contemplating the use of higher-valent PCVs for older adults, supporting the efficient allocation of healthcare resources."

HEOR • Retrospective data • Infectious Disease • Pneumococcal Infections

RATES OF INFLUENZA AND PNEUMOCOCCAL VACCINATION AND CORRELATION WITH SURVIVAL IN MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SURVEY (EHA 2025) - "FV was performed in more than 70% of patients while less than a half of patients received PV, in one third of cases with a sub-optimal sequential administration of a polysaccharide vaccine (Pneumovax) followed by a pneumococcal conjugate vaccine (Prevnar13 or Prevnar20). In MM a response to PV is detectable, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression, even if a drop in the serum response overtime suggests the need of a dedicated schedule with a multidisciplinary approach, especially in the setting of RRMM patients."

Clinical • Pneumococcal vaccines • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Oncology • Pneumococcal Infections • Psychiatry • Respiratory Diseases

Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based Markov model. (PubMed, Infect Dis Now) - "Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

The Value of Pneumovax Testing in the Prevnar 20 Era (CIS 2025) - "Even in subjects who have previously received PCV13 or PCV20, there is still diagnostic utility in administration of PPSV23 and evaluation of the response to the unique serotypes as a means of assessing anti-polysaccharide antibody responses."

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric national immunization program. (PubMed, J Med Econ) - "The majority of sensitivity and scenario analyses of both pairwise comparisons were aligned with the base case. The results of this analysis indicate that PCV20 implementation into the Romanian pediatric NIP would greatly reduce pneumococcal disease burden and would be a cost-effective approach versus PCV13 or PCV15 from a societal perspective over 10 years."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Apr 2025 ➔ Sep 2025 | Trial primary completion date: Apr 2025 ➔ Sep 2025

Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

An Italian cost-utility analysis of 20-Valent pneumococcal conjugate vaccine for routine vaccination in infants. (PubMed, J Med Econ) - "The introduction of PCV20 as a vaccination strategy for children in Italy represents a cost-effective and clinically advantageous option. Its implementation can reduce the burden of pneumococcal disease and associated healthcare costs, improving public health outcomes and the economic efficiency of the healthcare system."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections

Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules. (PubMed, Infect Dis Ther) - "The comparable immunogenicity of PCV20 versus PCV10 in 2 + 1 and 3 + 1 schedules suggests that PCV20 will have similar effectiveness for the ten serotypes included in both vaccines, including for direct protection during infancy and toddler age, while also expanding serotype coverage. Effectiveness for PCV20 needs to be confirmed in post-marketing studies."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (clinicaltrials.gov) - P2 | N=800 | Recruiting | Sponsor: Pfizer | N=500 ➔ 800 | Trial completion date: Aug 2026 ➔ May 2027 | Trial primary completion date: Aug 2026 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis. (PubMed, Hum Vaccin Immunother) - "The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

IS39 - Fighting foes, old and new: maintaining and expanding direct protection against persistent and emerging serotypes in adults with pneumococcal vaccination (ESCMID Global 2025) - "Pneumococcal vaccination with PCV20 can help reduce the burden of vaccine preventable respiratory diseases by providing direct protection against some of the most clinically relevant pneumococcal serotypes causing disease in adults. In this symposium we will discuss the evolving epidemiological pneumococcal landscape and how higher valent vaccines can help ensure maintenance and expanded coverage of some of the serotypes that cause a significant burden of disease in vulnerable populations."

Clinical • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections • Respiratory Diseases

A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. (PubMed, Vaccine) - P3 | "The safety and tolerability profile of PCV20 was similar to PCV13. Trial registration:Clinicaltrials.gov, NCT05408429."

Journal • P3 data • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Insights into Insurance for Vaccine Coverage Patients on Specialty Medications (CRA-AHPA 2025) - "Full vaccination in the public insurance group were as follows: Influenza (81/132, 61.4%), COVID-19 (99/132, 75.0%), Prevnar 13 or 20 (75/132, 56.8%), Pneumovax 23 (106/132, 80.3%), and Shingrix (41/132, 31.1%). Overall, there were several important findings. The group with the highest vaccination rate across all categories were those possessing two or more insurance plans. Higher rates of influenza and Pneumovax 23 vaccination were seen in the public insurance group, but this is likely due to a majority of this group being older than 65 (age required for free Pneumovax coverage) and the general trend of increased influenza vaccination in older adults.[2] Prevnar and Shingrix vaccination rates were seemingly similar for public and private groups, however sub-group analysis presented an important finding."

Clinical • Reimbursement • US reimbursement • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Utah | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections